Article
Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.
Leukemia - 1 Jun 2026
Yan Yuting, Chen Weihao, Yu Ying, Li Yuxi, Xiong Wenjie, Zhang Xinyi, Wang Tingyu, Liu Wei, Sui Weiwei, Yu Zhen, Hao Mu, An Gang, Zou Dehui, Qiu Lugui, Yi Shuhua
Abstract excerpt
Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoma with marked clinical and molecular heterogeneity. Clinical risk models, including IPSSWM, rIPSSWM, and MSSWM, were developed prior to the widespread use of Bruton tyrosine kinase inhibitors (BTKi), and their performance in the BTKi era remains uncertain. In addition, the prognostic impact of various genomic alterations is controversial. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.